Induced pluripotent stem cell technology: a decade of progress
By Yanhong Shi, H. Inoue, Joseph C. Wu, S. Yamanaka. Nature reviews. Drug discovery, 2016
1,318 citations recorded by the source corpus.
Since the advent of induced pluripotent stem cell (iPSC) technology a decade ago, enormous progress has been made in stem cell biology and regenerative medicine. Human iPSCs have been widely used for disease modelling, drug discovery and cell therapy development. Novel pathological mechanisms have been elucidated, new drugs originating from iPSC screens are in the pipeline and the first clinical trial using human iPSC-derived products has been initiated. In particular, the combination of human iPSC technology with recent developments in gene editing and 3D organoids makes iPSC-based platforms even more powerful in each area of their application, including precision medicine. In this Review, we discuss the progress in applications of iPSC technology that are particularly relevant to drug discovery and regenerative medicine, and consider the remaining challenges and the emerging opportunities in the field.
Subfields: Biomedical Engineering, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/887d12d3a1dbf54c7dad41d9a19c9399d7e208d1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biomedical Engineering
In Molecular Biology
Citations in the corpus
- Magnetically actuated microrobots as a platform for stem cell transplantation (2019, background): “Numerous types of stem cells, which can be embryonic, adult, or induced pluripotent, are available from various sources (3, 4).”
- Current Challenges of iPSC-Based Disease Modeling and Therapeutic Implications (2019, background): “New pharmacological candidates stemming from iPSC-based high throughput screens are in the pipeline [17].”